No Evidence of EBV Reactivation Risk with Hydroxychloroquine in RA
Hydroxychloroquine (HCQ) does not pose a documented risk of reactivating or worsening Epstein-Barr virus (EBV) infection in patients with rheumatoid arthritis, and may actually provide antiviral benefits.
Key Evidence
The available guidelines and research do not identify HCQ as a medication associated with viral reactivation risk. In fact, the evidence suggests the opposite:
HCQ's Immunomodulatory Profile
HCQ has immunomodulatory rather than immunosuppressive effects 1. This is a critical distinction—unlike truly immunosuppressive agents that increase viral reactivation risk, HCQ modulates immune responses without significantly compromising antiviral immunity.
Documented Antiviral Properties
Research demonstrates that HCQ possesses antiviral effects against multiple viruses 2. In HIV-infected patients with inflammatory arthritis, HCQ treatment resulted in:
- A 1-log decrease in recoverable viral RNA
- Improved immune responses
- Decreased inflammatory markers (IL-6)
- No development of opportunistic infections 2
Risk Stratification from Guidelines
The comprehensive 2017 Gastroenterology guidelines on viral reactivation with immunosuppressive therapies 3 extensively categorize medications by reactivation risk for hepatitis B virus. HCQ is notably absent from all risk categories (high, moderate, or low risk), while other RA medications are specifically listed:
High-risk agents include:
- B-cell depleting therapies (rituximab)
- TNF-α inhibitors (infliximab, adalimumab)
- High-dose corticosteroids
Low-risk agents include:
- Methotrexate
- Azathioprine
- Low-dose corticosteroids (<10 mg prednisone daily)
Clinical Practice Guidance
The 2016 ACR RA treatment guidelines 4 recommend HCQ as a safe option for patients with hepatitis C infection, noting it can be used when minimizing immunosuppression is desired. The 2021 ACR guidelines 5 conditionally recommend hydroxychloroquine as a preferred initial therapy for DMARD-naive patients with low disease activity specifically because it is better tolerated and has a more favorable risk profile.
Respiratory Infection Data
A large registry study of RA patients found no increased risk of respiratory infections (including upper respiratory infections, bronchitis, and pneumonia) in patients receiving HCQ compared to other conventional DMARDs (HR=0.87,95% CI 0.70-1.07) 6. This further supports HCQ's safety profile regarding viral infections.
Clinical Recommendation
Continue HCQ therapy in RA patients without concern for EBV reactivation. The drug's immunomodulatory mechanism, documented antiviral properties, and absence from viral reactivation risk stratifications in major guidelines all support its safety. Unlike biologics or high-dose immunosuppressants that require viral monitoring, HCQ does not warrant special precautions regarding EBV status.
Important Caveats
- Monitor for HCQ's known adverse effects (retinopathy, cardiac effects) per standard protocols 7
- The FDA label notes HCQ's anti-inflammatory and immunomodulatory (not immunosuppressive) mechanism 7
- If combining HCQ with other DMARDs that do carry viral reactivation risk (such as rituximab or high-dose TNF inhibitors), follow appropriate viral screening and monitoring protocols for those agents specifically